DiuTinus ImmunoTherapeutics Inc.
Industry: Cancer therapy
DiuTinus ImmunoTherapeutics is developing a novel treatment for B cell lymphoid diseases. The treatment is based on a discovery of a subset of T cells that have stem cell-like memory (CAR-Tscm cells). The company aims to improve survival rates and/or application safety compared to existing chimeric antigen receptor (CAR) T cell therapy, which has major limitations.
DiuTinus is planning to demonstrate better safety and effectiveness in the treatment of patients with relapsed or refractory lymphoid malignancies. The company is also working to design Phase 1 clinical trials to evaluate CAR-Tscm therapy for subjects with non-Hodgkin lymphoma.